Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension

European Respiratory Journal

Volumn 12, Issue 2, 1998, Pages 265-270

  Sitbon, O ^a,b   Humbert, M ^a   Jagot, J L ^a   Taravella, O ^a   Fartoukh, M ^a   Parent, F ^a   Herve, P ^a   Simonneau, G ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b Serv de Pneumologie et Reanimation   (France)

Author keywords

Calcium channel blockers; Nitric oxide; Primary pulmonary hypertension; Vasodilator challenge

Indexed keywords

ACENOCOUMAROL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NIFEDIPINE; NITRIC OXIDE; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODYNAMICS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG RESISTANCE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SHOCK; TREATMENT OUTCOME; VASODILATATION;

EID: 0031869664     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12020265     Document Type: Article

References (19)

1. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.
2. Weir EK. Acute vasodilator testing and pharmacological treatment of primary pulmonary hypertension. In: Fishman AP, ed. The pulmonary circulation: normal and abnormal. Mechanisms, management and the national registry. Philadelphia, PA, University of Pennsylvania Press 1990; pp. 485-499.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
4. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-141.
5. Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 1991; 18: 1323-1327.
6. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
7. Hoeper MM, Wilke T, Weite T, Breuer HWM, Wagner TOF. How effective is the treatment with high-dose nifedipine for primary pulmonary hypertension? Semin Respir Crit Care Med 1994; 15: 490-494.
8. Partanen J, Nieminen MS, Luomanmaki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med 1993; 329: 812.
9. Farber HW, Karlinskz JB, Faling LJ. Fatal outcome following nifedipine for primary pulmonary hypertension. Chest 1983; 83: 708-709.
10. Aromatorio GJ, Uretsky BF, Reddy PS. Hypotension and sinus arrest with nifedipine in pulmonary hypertension. Chest 1985; 87: 265-267.
11. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term testing with prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484-488.
12. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
13. Simonneau G, Herve P, Petitpretz P, et al. Detection of a reversible component in primary pulmonary hypertension: value of prostacyclin acute infusion. Am Rev Respir Dis 1986; 133: A223.
14. Palevsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990; 82: 2018-2026.
15. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66: 334-338.
16. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-1174.
17. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223.
18. Packer M. Is it ethical to administer vasodilator drugs in patients with primary pulmonary hypertension? Chest 1989; 95: 1173-1175.
19. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986; 134: 342-346.